A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Bausch & Lomb Incorporated
- Study ID
- NCT07128628
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination — DRUGTopical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
- Lifitegrast — DRUGTopical ocular drop of lifitegrast administered for 4 weeks
- Perfluorohexyloctane — DRUGTopical ocular drop of perfluorohexyloctane administered for 4 weeks
- Vehicle — DRUGTopical ocular drop with no active ingredients administered for 4 weeks
- Vehicle — DRUGTopical ocular drop with no active ingredients administered for 4 weeks
- Vehicle — DRUGTopical ocular drop with no active ingredients administered for 4 weeks
Study Details
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Key Dates
- Start date
- Oct 24, 2025
- Status verified
- Mar 2026
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 423 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1
- Active Comparator: Arm 2
- Active Comparator: Arm 3
- Placebo Comparator: Arm 4
- Placebo Comparator: Arm 5
- Placebo Comparator: Arm 6
Primary Outcome Measure
Total corneal fluorescein staining change from baseline [ Time Frame: Baseline, day 29 ]
Central Contacts
- Study Manager Bausch and Lomb2147262850
Locations (32)
Find similar trials in Phoenix, AZ
Related Studies
- Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).PHASE2 · Recruiting · Instituto Grifols, S.A. · Glendale, California
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseasePHASE3 · Recruiting · AbbVie · Dothan, Alabama
- 2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHDRecruiting · University of Maryland, Baltimore · Baltimore, Maryland